cilostamide has been researched along with Cardiac Failure in 6 studies
cilostamide: selective inhibitor of cyclic AMP phosphodiesterase & platelet aggregation; structure
| Excerpt | Relevance | Reference |
|---|---|---|
| "The β-blockers carvedilol and metoprolol provide important therapeutic strategies for heart failure treatment." | 3.80 | Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium. ( Berk, E; Christ, T; Engel, A; Galindo-Tovar, A; Gillette, KT; Kaumann, AJ; Molenaar, P; Ravens, U, 2014) |
| "Heart failure was induced in male Wistar rats by coronary artery ligation." | 1.36 | Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. ( Aronsen, JM; Hougen, K; Levy, FO; Moltzau, LR; Nguyen, CH; Osnes, JB; Qvigstad, E; Sjaastad, I; Skomedal, T, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orstavik, O | 1 |
| Ata, SH | 1 |
| Riise, J | 1 |
| Dahl, CP | 1 |
| Andersen, GØ | 1 |
| Levy, FO | 3 |
| Skomedal, T | 3 |
| Osnes, JB | 3 |
| Qvigstad, E | 2 |
| Molenaar, P | 1 |
| Christ, T | 1 |
| Berk, E | 1 |
| Engel, A | 1 |
| Gillette, KT | 1 |
| Galindo-Tovar, A | 1 |
| Ravens, U | 1 |
| Kaumann, AJ | 1 |
| Hubert, F | 1 |
| Belacel-Ouari, M | 1 |
| Manoury, B | 1 |
| Zhai, K | 1 |
| Domergue-Dupont, V | 1 |
| Mateo, P | 1 |
| Joubert, F | 1 |
| Fischmeister, R | 1 |
| Leblais, V | 1 |
| Moltzau, LR | 1 |
| Aronsen, JM | 2 |
| Nguyen, CH | 1 |
| Hougen, K | 1 |
| Sjaastad, I | 2 |
| Hussain, RI | 1 |
| Afzal, F | 1 |
| Krobert, KA | 1 |
| Tarpey, SB | 1 |
| Sawmiller, DR | 1 |
| Kelly, C | 1 |
| Thompson, WJ | 1 |
| Townsley, MI | 1 |
6 other studies available for cilostamide and Cardiac Failure
| Article | Year |
|---|---|
Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydraz | 2014 |
Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Cyclic Nucleotide Phosphodiesterases, Ty | 2014 |
Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4.
Topics: Adrenergic beta-Agonists; Animals; Aorta, Thoracic; Cyclic Nucleotide Phosphodiesterases, Type 3; Cy | 2014 |
Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition.
Topics: Animals; Apoptosis; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide | 2010 |
The functional activity of inhibitory G protein (G(i)) is not increased in failing heart ventricle.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Animals; Carbachol; Cardiotonic Agents; GTP-Binding Pro | 2013 |
Phosphodiesterase 3 activity is reduced in dog lung following pacing-induced heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Capillaries; Capillary Permeability; Colforsin; Cyclic | 2003 |